Skip to main content

Online Only

Lynparza FDA Approved, in Combination With Abiraterone and Prednisone (or Prednisolone), for Metastatic Castration-Resistant Prostate Cancer With BRCA Mutation

Epkinly FDA Approved for Relapsed or Refractory Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma

Polivy Received New Indication for First-Line Treatment of Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, and High-Grade B-Cell Lymphoma

Original Research, Practice Management, Oncology

Trends in Utilization, Prices, and Spending for Oral Medications for Breast Cancer Treatment in the US Medicaid Population, 2008-2019

Fatimah Hussain Alyami, BPharm, MS, PhD; Jeff Jianfei Guo, BPharm, PhD

Jemperli (Dostarlimab) First Immunotherapy Approved for Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer

Loretta Fala

Ukoniq (Umbralisib) FDA Approved for Adults with Relapsed or Refractory Marginal-Zone Lymphoma or Follicular Lymphoman

Loretta Fala

Tabrecta (Capmatinib) First FDA-Approved Drug for Metastatic NSCLC with MET Exon 14 Skipping Mutation

Loretta Fala

Abecma (Idecabtagene Vicleucel) First-in-Class BCMA-Directed CAR T-Cell Therapy Approved for Relapsed or Refractory Multiple Myeloma

Loretta Fala

Truseltiq (Infigratinib) New Targeted Therapy FDA Approved for Advanced or Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations

Loretta Fala

Politics and Healthcare: Drug Pricing Dynamics Leading Up to the 2020 Election

Gary Branning, MBA; Kathryn Hayes, BA

Page 2 of 2
Results 11 - 20 of 20